Sean McClain

“AppSite continues to execute, and I'll walk you through recent highlights, including key progress on ongoing headline trial, our new partnership with UI Willie, and our $100 million financing completed at the end of June.”

“We've built an AI-native platform at Absi where we're able to accelerate the time it takes to get new drugs to the clinic and overall reducing the timelines, and we'll talk more about that on later slides, and really creating an exciting, differentiated pipeline that's focused on prolactin receptor biology.”

“Where we are on ADS 201, a new addition to our prolactin pipeline, and the strategy driving both. 2026 is going to be a data-rich year for AppSci, with multiple readouts in front of us.”

“ABS-201 is in the clinic, and we have dosed our first three SAD cohorts in our Phase I 2A headline trial with favorable emerging safety data.”

“Today, we will be sharing updates about our pipeline, including interim phase one results for ABS-101, acceleration of ABS-201 development in androgenetic alopecia, and expansion of ABS-201 development in a second indication, endometriosis.”